Literature DB >> 3627379

(-)-Propranolol and (+/-)-cyanopindolol are mixed agonists-antagonists at serotonin autoreceptors in the hippocampus of the rat brain.

G Maura, M Ulivi, M Raiteri.   

Abstract

The effects of (-)-propranolol, (+)-propranolol and (+/-)-cyanopindolol on the release of [3H]5-hydroxytryptamine [( 3H]5-HT) were investigated in synaptosomes from the hippocampus of the rat, depolarized in superfusion with 15 mM KCl. (-)-Propranolol, but not (+)-propranolol, inhibited in a concentration-dependent way the K+-evoked release of [3H]5-HT. (+/-)-Cyanopindolol behaved similarly but was about 10 times more potent than (-)-propranolol. The inhibitory effects of (-)-propranolol and (+/-)-cyanopindolol were prevented by the autoreceptor antagonist methiothepin. Both beta-adrenoceptor antagonists antagonized the inhibition by exogenous 5-HT of the K+-evoked release of [3H]5-HT. The data suggest that some beta-adrenoceptor antagonists may behave as mixed agonists-antagonists at the 5-HT autoreceptor. Synaptosomes in superfusion appear to be particularly suitable to study separately agonistic compared to antagonistic activity of compounds having a mixed agonist-antagonist profile.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3627379     DOI: 10.1016/0028-3908(87)90232-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  14 in total

1.  Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain.

Authors:  P C Waldmeier; M Williams; P A Baumann; S Bischoff; M A Sills; R F Neale
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

Review 2.  Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man.

Authors:  P Turner
Journal:  Postgrad Med J       Date:  1989-01       Impact factor: 2.401

3.  5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some beta-adrenoceptor antagonists.

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

4.  Maternal defense is modulated by beta adrenergic receptors in lateral septum in mice.

Authors:  Melissa-Ann L Scotti; Grace Lee; Stephen C Gammie
Journal:  Behav Neurosci       Date:  2011-06       Impact factor: 1.912

5.  Characterization of a 5-HT1B receptor on CHO cells: functional responses in the absence of radioligand binding.

Authors:  H Giles; S J Lansdell; M L Bolofo; H L Wilson; G R Martin
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  5-Hydroxytryptamine 5-HT1B receptors inhibiting cyclic AMP accumulation in rat renal mesangial cells.

Authors:  P Schoeffter; J Pfeilschifter; I Bobirnac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

7.  Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptors similar to the 5-HT 1D subtype.

Authors:  G J Molderings; K Werner; J Likungu; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

8.  G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes.

Authors:  K Ariani; M W Hamblin; G L Tan; C A Stratford; R D Ciaranello
Journal:  Neurochem Res       Date:  1989-09       Impact factor: 3.996

9.  Inhibition of noradrenaline release via presynaptic 5-HT1B receptors of the rat vena cava.

Authors:  G J Molderings; K Fink; E Schlicker; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

10.  Species differences in presynaptic serotonin autoreceptors: mainly 5-HT1B but possibly in addition 5-HT1D in the rat, 5-HT1D in the rabbit and guinea-pig brain cortex.

Authors:  N Limberger; R Deicher; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.